TFS Capital’s Epirus Biopharmaceuticals EPRS Stock Holding History
Bought
Maintained
Sold
Other funds holding EPRS
TFS Capital's EPRS Position: Q4 2015 in Review
TFS Capital sold out of Epirus Biopharmaceuticals (EPRS) in Q4 2015, closing a stake of 80,294 shares — an estimated $355K sold.
TFS Capital first reported a position in EPRS in Q1 2015 and held it in 3 quarters. The position peaked at $355K in Q3 2015. 45 funds tracked by Wall St. Rank hold EPRS as of Q4 2015.
- TFS Capital reported no remaining Epirus Biopharmaceuticals position as of Q4 2015 after selling out during the quarter.
- TFS Capital sold 80,294 Epirus Biopharmaceuticals shares in Q4 2015, an estimated $355K.
- TFS Capital first reported a position in Epirus Biopharmaceuticals in Q1 2015 and held it in 3 quarters.
- TFS Capital's Epirus Biopharmaceuticals position peaked at $355K in Q3 2015.
- 45 funds tracked by Wall St. Rank held Epirus Biopharmaceuticals as of Q4 2015.
Based on TFS Capital's 13F filing for Q4 2015, filed 29 Jan 2016.